CompletedPhase 1NCT01682538

Bioequivalence of Orfadin Suspension Compared to Orfadin Capsules, and the Effect of Food on the Bioavailability of the Suspension

Studying Catastrophic antiphospholipid syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Swedish Orphan Biovitrum
Principal Investigator
Erik Brouwer, MD
Swedish Orphan Biovitrum
Intervention
Nitisinone, capsule(drug)
Enrollment
12 enrolled
Eligibility
18-55 years · MALE
Timeline
20122012

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01682538 on ClinicalTrials.gov

Other trials for Catastrophic antiphospholipid syndrome

Additional recruiting or active studies for the same condition.

See all trials for Catastrophic antiphospholipid syndrome

← Back to all trials